Treatment patterns and costs in cutaneous squamous cell carcinoma (CSCC) patients with nodal dissection, chemotherapy, and/or radiation therapy.

Ruiz, Emily S.; Chen, Chieh-I; Deering, Kathleen L.; Xu, Yu; Kuznik, Andreas; Sasané, Medha; Ye, Fen; Harshaw, Qing; Andria, Michael L.; Fury, Matthew G.; Singh, Kirandeep; Schmults, Chrysalyne D.

doi:10.1200/jco.2018.36.15_suppl.e18703

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Therefore, advanced cutaneous squamous cell carcinoma is a life-threatening condition for patients who are treated with cytotoxic chemotherapy or EGFR inhibitors, and it is associated with substantial morbidity, impact on quality of life, and health-care burden. [8][9][10] Patients older than 65 years are more likely than younger patients to require dose reductions in the first cycle of chemotherapy, underscoring the need for new treatment approaches for patients with advanced cutaneous squamous cell carcinoma, a predominantly elderly population. 11,12 Because of ultraviolet-mediated mutagenesis, the median tumour mutational burden of cutaneous squamous cell carcinoma is approximately 45 mutations per megabase, three times higher than that of skin melanoma.…”

Section: Introductionmentioning

confidence: 99%

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Migden

Khushalani

Chang

et al. 2020

The Lancet Oncology

365

392

View full text Add to dashboard Cite

DR recruited patients and collected the data. SL did the data analysis. All authors contributed to data interpretation, as well as critical review, revision, and approval of the report. Data sharingQualified researchers can request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this report. Individual anonymised participant data will be made available once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Requests should be submitted on the Regeneron website.

show abstract

Section: Introductionmentioning

confidence: 99%

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Migden

Khushalani

Chang

et al. 2020

The Lancet Oncology

365

392

View full text Add to dashboard Cite

show abstract

“…Therefore, advanced cSCC is a life-threatening condition for patients treated with cytotoxic chemotherapy or EGFR inhibitors and is associated with substantial morbidity, quality of life impact, and health care burden. Patients over 65 years of age are more likely than younger patients to require dose reductions in the first cycle of chemotherapy, emphasizing the need for new therapeutic approaches in a predominantly elderly population ( 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives

Alberti

Bossi

2022

Front. Oncol.

View full text Add to dashboard Cite

Although initial surgical excision cures 95% of patients, a minority of cutaneous squamous cell carcinomas (cSCCs) are judged to be unresectable, either locally advanced or with unresectable regional lymph nodes or distant metastases. These patients are offered systemic treatments. Response rate to chemotherapy is relatively low and not durable, as well as the results obtained with epidermal growth factor inhibitors (EGFRi). Like other cutaneous tumors, cSCCs have high immunogenicity, driven by the high mutational burden, the ultraviolet signature, and the overexpressed tumor antigens. Two checkpoint inhibitors, cemiplimab and pembrolizumab, achieved high response rate and survival with fewer toxicities than other available systemic agents. These promising results prompted to investigate new combination strategies of systemic therapy and surgery or radiotherapy. Subgroup analysis showed promising role of immunotherapy to facilitate surgery in locally advanced cSCC and, in a small group of patients, long-term survivals without resection. However, some cSCCs treated with immunotherapy develop either early or late resistance, so new drugs and new combinations are in a clinical study to overcome the mechanism underpinning these resistances. The present review focuses on the progress with immunotherapy to date and on new therapeutic strategies for cSCC.

show abstract

“…Until the advent of immunotherapy, systemic therapies for HNCSCC were limited to cytotoxic platinum-based chemotherapy and salvaged with targeted therapy inhibiting the epidermal growth factor receptor (EGFR) [ 9 ]. These therapies are associated with poor response rates, short duration of response, and substantial morbidity and toxicity, especially in patients of advanced age [ 10 , 11 , 12 , 13 ]. Since the Food and Drug Administration (FDA) approval of cemiplimab in 2018 and pembrolizumab in 2020, immunotherapy has become the standard of care for patients with locally advanced or mHNCSCC that is not amenable to curative surgery or RT [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma

Khorasanchi

Kendra

et al. 2022

Cancers

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (CSCC) is the second most common non-melanoma skin cancer. A majority of patients present with localized disease, but some can present with locally advanced or metastatic disease. Most of these advanced cases occur in the anatomical head and neck region and are associated with more aggressive disease, necessitating prompt and effective treatment. Prior to the emergence of immunotherapy, systemic treatment options were limited to platinum-based chemotherapy and salvaged with targeted epidermal growth factor therapy. These therapies were associated with poor efficacy and increased toxicity in an often frail, older population. Immunotherapy has dramatically improved outcomes in this patient population due to its favorable side effect profile, durable treatment response, and improved overall outcomes. In this review, an overview of the recent advances of immunotherapy in the management of CSCC in the anatomical head and neck region is provided, with a focus on advanced presentations.

show abstract

Treatment patterns and costs in cutaneous squamous cell carcinoma (CSCC) patients with nodal dissection, chemotherapy, and/or radiation therapy.

Cited by 6 publications

References 0 publications

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives

Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma

Contact Info

Product

Resources

About